Roche has shared the numbers behind its phase 3 win in primary progressive multiple sclerosis (PPMS), linking its BTK ...

Roche Holdings AG RHHBY on Monday shared new late-breaking data from the Phase 3 FENtrepid study of the investigational ...

TG Therapeutics is gearing up for a new clinical trial, dubbed ULTIMATE, to test Briumvi in children and adolescents with ...

About 1 million people are living with multiple sclerosis in the U.S., and about 10% of those have PPMS, making it the least common form of the disease.

A new study reveals how Epstein-Barr virus may provoke immune cells to attack the brain, offering fresh hope for treating ...

Cerebrospinal fluid (CSF)-based molecular tests can reliably distinguish multiple sclerosis (MS) from other neurological ...

Background Physical activity has been associated with neuroprotective and immunomodulatory benefits, potentially influencing ...

BERLIN, Feb 7 () - Swiss pharmaceutical company Roche said on Saturday its experimental ​multiple sclerosis drug fenebrutinib ...

Multiple sclerosis B-cell profiles differ by ancestry and sex among Black and Hispanic patients with multiple sclerosis.

New research shows early Multiple Sclerosis brain damage is dynamic and reversible. Myelin swellings can shrink and disappear based on nerve activity.

Researchers at UC San Francisco have uncovered a new clue to how Epstein-Barr virus (EBV) could contribute to multiple ...

Biogen swung to a loss as results were hurt by a double-digit decline in revenue from its core multiple sclerosis treatments.